WO2021226431A1 - Dimers for use in synthesis of peptidomimetics - Google Patents
Dimers for use in synthesis of peptidomimetics Download PDFInfo
- Publication number
- WO2021226431A1 WO2021226431A1 PCT/US2021/031246 US2021031246W WO2021226431A1 WO 2021226431 A1 WO2021226431 A1 WO 2021226431A1 US 2021031246 W US2021031246 W US 2021031246W WO 2021226431 A1 WO2021226431 A1 WO 2021226431A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- aza
- compounds
- peptide
- group
- Prior art date
Links
- 0 *C(*)C(NN(*)C(*)=O)=O Chemical compound *C(*)C(NN(*)C(*)=O)=O 0.000 description 2
- YKFZZIWZOKCJQW-UHFFFAOYSA-N CC(C)(C)Oc1ccc(CCC(Cl)=O)cc1 Chemical compound CC(C)(C)Oc1ccc(CCC(Cl)=O)cc1 YKFZZIWZOKCJQW-UHFFFAOYSA-N 0.000 description 1
- AQRSJKRHKRPAOC-UHFFFAOYSA-N CCCCCC(C(C)NC(SCC)=O)C(CCc(cc1)ccc1OC(C)(C)C)=O Chemical compound CCCCCC(C(C)NC(SCC)=O)C(CCc(cc1)ccc1OC(C)(C)C)=O AQRSJKRHKRPAOC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/12—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Definitions
- DIMERS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS [0001] This application claims the benefit of U.S. Provisional Application No.63/021,803, filed on May 8, 2020, hereby incorporated by reference.
- Field of the Invention [0002] The present invention is directed to dimers for use in synthesis of azapeptides and other aza-amino acid conjugates; synthesis of azapeptides and other aza-amino acid conjugates, and uses of azapeptides and other aza-amino acid conjugates in drug discovery, diagnosis, prevention, inhibition, and treatment of diseases.
- Azapeptides are analogs of peptides.
- An azapeptide contains a substituted semicarbazide instead of one or more of the amino acid residue(s) of a parent peptide.
- one or more of ⁇ -carbon atom(s) of the parent peptide are replaced with a nitrogen atom in the azapeptide.
- azapeptides contain a nitrogen atom instead of one or more of ⁇ -carbon atom(s).
- an aza-peptide bond is more stable under the effect of peptidases, and consequently azapeptides are hydrolysed and degraded by peptidases at a slower rate and exhibit, e.g., an impoved metabolic stability, than the parent peptides.
- the rate of formation of the aza-peptide bond is much slower than that of a typical peptide bond. Thus, there is a greater potential of formation of unwanted side products during azapeptide synthesis with aza-amino acids than with conventional amino acids.
- the invention provides dimers for use as building blocks or synthons for synthesis of analogues of peptides (“peptidomimetic agents”).
- the dimers are stable entities and may be stored (e.g., as powder) for extended periods of time without being compromised.
- the dimers are stable at 37°C in an aqueous medium (e.g., an aqueous solution) with a pH of about 7 (e.g., distilled water) for at least 30 minutes, 60 minutes, 90 minutes, 1 hour, 2 hours, 3 hours, 4 hours or 5 hours.
- the dimers are capable of being activated under milder conditions and at lower temperatures.
- the invention is directed in part to the compounds of Formula (I): and salts thereof, wherein A is N-phthalimidyl (NPhth) or NR 3 R 4 , wherein (i) R 3 is H and R 4 is tert- butoxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (Fmoc) or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl (Ddz) or (ii) R 3 and R 1 are connected and together form a side chain radical of proline and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl
- a 1 is absent when Z 1 is N; and A 2 is absent when Z 2 is N.
- the invention is also directed in part to the compounds of Formula (I): and salts thereof, wherein A is N-phthalimidyl or NR 3 R 4 , wherein (i) R 3 is H and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl or (ii) R 3 and R 1 are connected and together form a side chain radical of proline and R 4 is tert- butoxycarbonyl, 9-fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2- yloxycarbonyl; A 1 is H or absent; A 2 is H or absent; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L; D is H,
- the invention is also directed in part to the compounds of Formula (I): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; A 1 is H; A 2 is H or absent; A 3 is H or absent; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- the invention is also directed in part to the compounds of Formula (I): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; A 1 is H; A 2 is H or absent; A 3 is H or absent; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N, and at least one of Z 1 and Z 2 is N.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphen
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- a 1 is H
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 are both N.
- A is tert-butoxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (Fmoc), or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl (Ddz);
- a 1 is H;
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L;
- D is H, Cl, an alkyl, an aryl or a heteroaryl;
- L is an alkyl, imidazolyl, benzotriazolyl;
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 are both C.
- the invention is further directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a hetero
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl and benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N
- at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is S-D
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N
- at least one of Z 1 and Z 2 is N.
- the invention specifically encompasses, e.g., compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D an alkyl (e.g., ethyl); R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is S-D
- D an alkyl (e.g., ethyl)
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N
- at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is O-L
- L is an alkyl, imidazolyl, or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N
- at least one of Z 1 and Z 2 is N.
- the invention specifically encompasses, e.g., compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N [0024]
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl, benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl
- X is selected from the group consisting of imidazolyl and benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N
- at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl
- X is S-D
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N
- at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is tert-butoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl
- X is O-L
- L is an alkyl, imidazolyl, or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N
- at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl, benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl, benzotriazo
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (I), wherein A 1 is H; A 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is further directed in part to the compounds of Formula (I): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl;
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L;
- D is H, Cl, an alkyl, an aryl or a heteroaryl;
- L is an alkyl, imidazolyl or benzotriazolyl;
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids;
- Z 1 and Z 2 is each independently C or N, and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA): and salts thereof, wherein A is N-phthalimidyl or NR 3 R 4 , wherein (i) R 3 is H and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl or (ii) R 3 and R 1 are connected and together form a side chain radical of proline and R 4 is tert- butoxycarbonyl, 9-fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2- yloxycarbonyl;
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1
- the invention is further directed in part to compounds of Formula (IA): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; A 1 is H; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl, benzotriazolyl; R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 is C or N.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- a 1 is H
- X is selected from the group consisting of imidazolyl, be
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl, benzotriazolyl; R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl or benzotriazolyl; R 1 is selected from the group consisting side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl or benzotriazolyl
- R 1 is selected from the group consisting side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is S-D
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- R 1 is selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention specifically encompasses, e.g., compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is an alkyl (e.g., ethyl); R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is S-D
- D is an alkyl (e.g., ethyl)
- R 1 is selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N, at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl
- X is O-L
- L is an alkyl, imidazolyl, benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N, at least one of Z 1 and Z 2 is N.
- the invention specifically encompasses of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl; X is O- L; L is imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N, at least one of Z 1 and Z 2 is N [0039]
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl, benzotriazolyl; R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl or benzotriazolyl; R 1 is selected from the group consisting side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl
- X is selected from the group consisting of imidazolyl or benzotriazolyl
- R 1 is selected from the group consisting side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl
- X is S-D
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- R 1 is selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is tert-butoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N, at least one of Z 1 and Z 2 is N.
- a 1 is H
- A is tert-butoxycarbonyl
- X is O-L
- L is an alkyl, imidazolyl, benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N, at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl, benzotriazolyl; R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl, benzotriazolyl
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl or benzotriazolyl; R 1 is selected from the group consisting side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl or benzotriazolyl
- R 1 is selected from the group consisting side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; R 1 is selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- a 1 is H
- A 9-fluorenylmethoxycarbonyl
- X is S-D
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- R 1 is selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N; and at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 and Z 2 is each independently C or N, at least one of Z 1 and Z 2 is N.
- a 1 is H
- A 9-fluorenylmethoxycarbonyl
- X is O-L
- L is an alkyl, imidazolyl, benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids
- Z 1 and Z 2 is each independently C or N, at least one of Z 1 and Z 2 is N.
- the invention is also directed in part to compounds of Formula (IA): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1 is selected from the group consisting of side chain radicals of amino acids.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl
- the invention is also directed in part to compounds of Formula (II): and salts thereof, wherein A is N-phthalimidyl or NR 3 R 4 , wherein (i) R 3 is H and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl or (ii) R 3 and R 1 are connected and together form a side chain radical of proline and R 4 is tert- butoxycarbonyl, 9-fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2- yloxycarbonyl;
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R
- the invention is also directed in part to compounds of Formula (II): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; A 1 is H; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- a 1 is H
- X is selected from the group consisting of imidazolyl, benzo
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention specifically encompasses compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is an alkyl (e.g., ethyl); and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention specifically encompasses compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A is tert-butoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is tert-butoxycarbonyl; X is O-L; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (II), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is further directed in part to the compounds of Formula (IB): and salts thereof, wherein A is N-phthalimidyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 is N; and Z 2 is CH or N.
- A is N-phthalimidyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of
- the invention is also directed in part to the compounds of Formula (IB): and salts thereof, wherein A is N-phthalimidyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids; Z 1 is CH or N, and Z 2 is N.
- A is N-phthalimidyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D, and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of
- the invention is also directed in part to compounds of Formula (IC): and salts thereof, wherein A is N-phthalimidyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; R 1 is selected from the group consisting of side chain radicals of amino acids.
- A is N-phthalimidyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 is selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III): and salts thereof, wherein A is N-phthalimidyl, tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; A 1 is H; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- A is N-phthalimidyl, tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- a 1 is H
- X is
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of H and side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention specifically encompasses compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is an alkyl (e.g., ethyl); and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention specifically encompasses compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A is tert-butoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of H and side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is tert-butoxycarbonyl; X is O-L; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of H and side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (III): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- the invention is also directed in part to compounds of Formula (IIIA): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, or 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-
- the invention is also directed in part to compounds of Formula (IV): and salts thereof, wherein A is N-phthalimidyl or NR 3 R 4 , wherein (i) R 3 is H and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl or (ii) R 3 and R 1 are connected and together form a side chain radical of proline and R 4 is tert- butoxycarbonyl, 9-fluorenylmethoxycarbonyl or 2-(3,5-dimethoxyphenyl)propan-2- yloxycarbonyl;
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D or O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1
- the invention is also directed in part to compounds of Formula (IV): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; A 1 is H, X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D or O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- a 1 is H
- X is selected from the group consisting of imidazolyl, benzotriazoly
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention specifically encompasses compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is S-D; D is an alkyl (e.g., ethyl); and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is specifically directed to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is O-L; L is imidazolyl or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A is tert-butoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H; A is tert-butoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is tert-butoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H
- A is 9-fluorenylmethoxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D and O-L
- D is H, Cl, an alkyl, an aryl or a heteroaryl
- L is an alkyl, imidazolyl or benzotriazolyl
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is selected from the group consisting of imidazolyl and benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- a 1 is H; A is 9-fluorenylmethoxycarbonyl; X is S-D; D is H, Cl, an alkyl, an aryl or a heteroaryl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV), wherein A 1 is H; A is 9-fluorenylmethoxycarbonyl; X is O-L; L is an alkyl, imidazolyl, or benzotriazolyl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- the invention is also directed in part to compounds of Formula (IV): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D or O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D or O-L
- the invention is also directed in part to compounds of Formula (IV): and salts thereof, wherein A is N-phthalimidyl; X is selected from the group consisting of imidazolyl, benzotriazolyl, S-D or O-L; D is H, Cl, an alkyl, an aryl or a heteroaryl; L is an alkyl, imidazolyl or benzotriazolyl; and R 1 and R 2 is each independently selected from the group consisting of side chain radicals of amino acids. [0096] In the compounds of the invention, R 1 and R 2 could each independently be, e.g., a side chain radical of a natural amino acid or a side chain radical of an unnatural amino acid.
- the side chain radical of the natural amino acid could be selected, e.g., from the group consisting of side chain radicals of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, threonine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, serine, proline and glutamine.
- side chain radicals of aspartic acid e.g., from the group consisting of side chain radicals of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, threonine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and
- R 1 and R 2 could each independently be selected from the group consisting of side chain radicals of glycine, alanine, valisone, serine, threonine, asparagine, glutamine, cysteine, CH 2 -SeH (SeH), isoleucine, leucine, methionine, lysine, aspartic acid, glutamic acid, arginine, phenylalanine, tyrosine, tryptophan, histadine, and proline.
- the side chain of the unnatural amino acid could be selected, e.g., from the group consisting of side chain radicals of ⁇ -amino acids (e.g., L- ⁇ -homotyrosine, ⁇ -alanine, L- ⁇ - homoasparagine, L- ⁇ -homoalanine, L- ⁇ -homophenylalanine, L- ⁇ -homoproline, L- ⁇ -holysine, L- ⁇ -homorarginine, L- ⁇ -proline, etc.), aliphatic amino acids (e.g., 6-aminohexanoic acid, 2- amino-3-methoxybutanoic acid, 1-aminocyclopentane-1-carboxylic acid, 2-(aminooxy)acetic acid, 6-aminohaxanoic acid, 2 - [2 - (amino) - ethoxy]-ethoxy ⁇ acetic acid), ⁇ -cyclohexyl-L– alanine
- the side chain of the unnatural amino acid could be a side chain radical of a non- proteinogenic amino acid.
- the non-proteinogenic amino acid could, e.g., be ornithine or citrulline.
- R 1 , R 2 and X could each independently be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 - C 6 alkyl (e.g., methyl), hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.) or a protecting group (e.g., Phth, Boc, Fmoc, Ddz, etc.).
- Any of the compounds of Formulas (I), (IA), (IB), (IC), (II), (III), and (IV) listed above may comprise one or more of the following:
- A is NR 3 R 4 , wherein R 3 is H and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl, 2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl;
- A is N-phthalimidyl;
- A is NR 3 R 4 , R 3 is H, R 4 is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl, and R 3 and R 1 are connected and together form a side chain radical of proline;
- X is selected from the group consisting of imidazolyl and benzotriazolyl;
- X is S-D; and D is an alkyl;
- the invention is further directed to the use of compounds of Formulas (I), (IA), (IB), (IC), (II), (III), and (IV) in the preparation of compounds of Formula (V): wherein is at the N-terminus and/or the C-terminus, and/or covalently bound to the N-terminus and/or the C-terminus, or at or adjacent to a cleavage or a hydrolysis site of the compound of Formula (V); wherein B is selected from the group consisting of hydrogen, -NH 2 , -NNH 2 , -CONH 2 , -COOR 3, -COOH, -COH, -COC 1 -C 4 alkyl, -COC 1 -C 4 haloalkyl, -OH, an amino acid, an aza amino acid, a 2 to 60 -mer peptide, a 2 to 60 -mer aza peptide, a 2 to 60 -mer azatide; D is selected from the group consisting of hydrogen
- the side chain radical of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, serine, threonine, cysteine and glutamine may be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 -C 6 alkyl (e.g., methyl), hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.) or a protecting group (e.g., Phth, Boc, F
- the side chain radical of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, serine, threonine, cysteine and glutamine may be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 -C 6 alkyl (e.g., methyl), hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.) or a protecting group (e.g., Phth, Boc, F
- compounds of Formula (V) are more resistant to hydrolysis and/or enzymatic degradation than compounds of Formula (VI). In some of these preferred embodiments, compounds of Formula (V) are more potent than compounds of Formula (VI), e.g., due to a better fit into a biological receptor. Compounds of Formula (V) could be used, e.g., in drug discovery, diagnosis, prevention and treatment of diseases.
- the invention is further directed to the use of compounds of Formulas (I), (IA), (IB), (IC), (II), (III), and (IV) in the preparation of compounds of Formula (V): wherein is adjacent to the N-terminus and/or the C-terminus of the compound of Formula (V); wherein B is selected from the group consisting of hydrogen, -NH 2 , -NNH 2 , -CONH 2 , -COOR 3, -COOH, -COH, -COC 1 -C 4 alkyl, -COC 1 -C 4 haloalkyl, -OH, an amino acid, an aza amino acid, a 2 to 60 -mer peptide, a 2 to 60 -mer aza peptide, a 2 to 60 -mer azatide; D is selected from the group consisting of –OR 4 , -OH, -NH 2 , -NNH 2, -NHCOCH 3, -NHCH 3 , -N
- the side chain radical of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, serine, threonine, cysteine and glutamine may be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 -C 6 alkyl (e.g., methyl), hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.) or a protecting group (e.g., Phth, Boc, F
- the side chain radical of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, serine, threonine, cysteine and glutamine may be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 -C 6 alkyl (e.g., methyl), hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.) or a protecting group (e.g., Phth, Boc, F
- compounds of Formula (V) are more resistant to hydrolysis and/or enzymatic degradation than compounds of Formula (VI). In some of these preferred embodiments, compounds of Formula (V) are more potent than compounds of Formula (VI), e.g., due to a better fit into a biological receptor. Compounds of Formula (V) could be used, e.g., in drug discovery, diagnosis, prevention, inhibition, and treatment of diseases.
- B of each compound is independently selected from the group consisting of hydrogen, -NH 2 , -NNH 2 , -CONH 2 , -COOR 3, -COC 1 -C 4 alkyl, -COC 1 -C 4 haloalkyl, -OH, an amino acid, an aza amino acid, a 2 to 60 -mer peptide, a 2 to 60 -mer aza peptide, a 2 to 60 -mer azatide; D of each compound is independently selected from the group consisting of –OR 4 , -NH 2 , -NNH 2, -NHCOCH 3, -NHCH 3 , -N(CH 3 ) 2 , -CONH 2 , -COOH, -COH, -COC 1 -C 4 alkyl, -COC 1 -C 4 haloalkyl, an amino acid, an aza amino acid,
- the side chain radical of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, may be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 -C 6 alkyl (e.g., methyl), hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.) or a protecting group (e.g., Phth, Boc, Fmoc, Ddz, etc.).
- the invention is further directed to the use of compounds of Formulas (I), (IA), (IB), (IC), (II), (III), and (IV) in the preparation of azabradykinin, including, e.g., aza-7 bradykinin, aza-2,8 bradykinin, aza-2 bradykinin, and aza-8 bradykinin:
- the invention is further directed to the use of dimers (e.g., di-azatides) described in U.S. Serial No.16/869,692, filed on May 8, 2020, U.S. Serial No.16/869,749, filed on May 8, 2020, and U.S. Serial No.16/869,794, filed on May 8, 2020, all three hereby incorporated by reference in their entireties, in preparation of azapeptides and other peptidomimetic agents.
- dimers e.g., di-azatides
- the invention is also directed in part to a method of preparing a compound of Formula (V), the method comprising a step of activating a compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III) or Formula (IV) to form an activated compound of Formula (I), Formula (II), Formula (III), or Formula (IV), a step of coupling the activated compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III), or Formula (IV) with N-terminal of an amino acid, N-terminal of an aza-mino acid, provided that, if a side chain of the amino acid or aza-amino acid contains a group selected from amino, amide, guanidino N, carboxyl, sulfhydryl, carboxyl, hydroxyl, indole, imidazole phenol, the group is protected with a protecting group selected from tert- butoxycarbonyl,
- compound of Formula (V) is deprotected, e.g., with hydrazine, piperadine, TFA, acetic acid, thioanisole, EDT, anisole, etc., to form the compound of Formula (V).
- compounds of Formula (I), Formula (IB), Formula (IC), Formula (II), Formula (III), and Formula (IV) are activated by iodomethane (MeI).
- the compound of Formula (IA), Formula (IB), Formula (IC), Formula (II), or Formula (III) is a phthalimide-protected carbamoyl imidazole and is activated, e.g., by MeI.
- the compounds of Formula (I), Formula (IB), Formula (IC), Formula (II), Formula (III), Formula (IV) are activated, e.g., by DIPEA in acetonitrile.
- the compound of Formula (IA), Formula (IB), Formula (IC), Formula (II) or Formula (III) is phthalimide-protected carbamoyl benzotriazole and is activated by DIPEA in acetonitrile.
- the invention is also directed in part to the compunds of Formula (VII): and salts thereof, wherein A is N-phthalimidyl or NR 3 R 4 , wherein R 3 is H and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl, 2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl, or R 3 and R 1 are connected and together form a side chain radical of proline; A 1 is hydrogen or absent; A 2 is hydrogen or absent; K is a halogen; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of natural amino acid and side chain radicals unnatural amino acid amino acids; Z 1 and Z 2 is each independently C or N.
- A is N-phthalimidyl or NR 3 R 4 , wherein R 3 is H and R 4 is tert-butoxycarbonyl, 9- fluorenylmethoxycarbonyl, 2-(3,5-dimethoxypheny
- the invention is also directed in part to the compunds of Formula (VII): and salts thereof, wherein A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; A 1 is H or absent; A 2 is H or absent; K is a halogen; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of natural amino acid and side chain radicals unnatural amino acid amino acids; Z 1 and Z 2 is each independently C or N.
- A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl
- a 1 is H or absent
- a 2 is H or absent
- K is a halogen
- R 1 and R 2 is each independently selected from the group consisting of side chain radicals of natural amino acid and side chain radicals unnatural amino
- the invention is also directed in part to the compunds of Formula (VII): and salts thereof, wherein A 1 is absent or H, A is tert-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, 2-(3,5- dimethoxyphenyl)propan-2-yloxycarbonyl; K is a halogen; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of natural amino acid and side chain radicals unnatural amino acid amino acids; Z 1 and Z 2 is each independently C or N, and at least one of Z 1 and Z 2 is N.
- compounds of Formula (VII) are stable compounds formed during azapeptide synthesis from the dimers of the invention, e.g., by an activation of compounds of Formula (I), Formula (IB), Formula (IC), Formula (II), Formula (III) and Formula (IV), wherein, X is S-D, and D is selected from the group consisting of alkyls, aryls and heteroaryls.
- compounds of Formula (VII) could be coupled, e.g., with N-terminal of an amino acid, N-terminal of an aza-mino acid, N-terminal of a compound according to Formula (I), Formula (IB), Formula (IC), Formula (II), Formula (III), Formula (IV), Formula (V), or Formula (VI).
- the invention is also directed in part to compounds of Formula (IV), wherein A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl; X is Cl; R 1 and R 2 is each independently selected from the group consisting of side chain radicals of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, serine, threoinine, methionine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, and glutamine; Z 1 and Z 2 is each independently C or N, and at least one of Z 1 and Z 2 is N.
- A is tert-butoxycarbonyl or 9-fluorenylmethoxycarbonyl
- X is Cl
- R 1 and R 2 is each independently selected from the group consisting
- compounds of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III) and Formula may be activated, e.g., by halonium reagents (e.g., trichloroisocyanuric acid (“TCCA), or a combination of tetrabutyl ammonium chloride (“TBACl”) with tetrabutyl ammonium chloride (“TBACl”)). TBACl enhaces reaction performance when added prior to TCCA.
- halonium reagents e.g., trichloroisocyanuric acid (“TCCA), or a combination of tetrabutyl ammonium chloride (“TBACl”) with tetrabutyl ammonium chloride (“TBACl”)
- compounds of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III) and Formula may be activated, e.g., with TCCA and TBCl to form a compound according Formula (VII), and coupling the activated compound with an amine.
- the amine could be selected from the group consisting of amino esters, esters of amino acids, amino esters of aza-amino acids, peptides, and aza-peptides.
- the reaction may be performed, e.g., in chloroform, dichloromethane, or acetone. In some embodiments, from about 0.5 to about 2 equivalents of TCCA and TBCl are used. In some embodiments, from about 1 to about 3 equivalents of the amine are used. In some embodiments, from about 1.1 to about 1.8 equivalents of TCCA and TBCl, and from about 1.0 to about 1.5 equivalents of the amine are used.
- the coupling may, e.g., be for a time period of from 15 minutes to 12 hours.
- the coupling may be completed in about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, or about 120 minutes.
- acetonitrile is used as a solvent both during the activating and coupling steps.
- demethylformamide is used as a solvent during the coupling step.
- the invention is directed to a process for synthesizing azapeptides (e.g., by solution phase synthesis), the method comprising activating a dimer with TCCA and TBCl to form a reactive acyl chloride, and coupling the reactive acyl chloride with an amine, wherein the dimer is a compound according to any one of Formulas (I)-(IV), the reactive amine chloride is a compound according to Formulas (VII), and the amine is selected from the group consisting of amino esters, esters of amino acids, amino esters of aza-amino acids, peptides, and aza-peptides.
- the amine is a peptide or an aza-peptide.
- the azapeptide is a compound according to Formula (V).
- the invention is also directed to a process for a systematic insertion of an aza-amino acid or an aza-amino acid segment(s) at a desired position(s) along the peptide sequence comprising activating a dimer with TCCA and TBCl to form in situ a reactive acyl chloride, and coupling the reactive chloride with an amine, wherein the dimer is a compound according to any one of Formulas (I)-(IV), and the reactive amine chloride is a compound according to Formula (XI).
- the amine could be selected, e.g., from the group consisting of amino esters, esters of amino acids, amino esters of aza-amino acids, peptides, and aza-peptides.
- the amine is a compound according to Formula (V).
- the invention is also directed to a method of preparing an azapeptide comprising a step of activating a compound according to Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III) or Formula (IV); and a step of coupling the activated compound with N-terminal of an amino acid, N-terminal of an aza-mino acid; wherein the azapeptide is a compound of Formula (V).
- the compound of Fomula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III) or Formula (IV) may be unsubstituted or substituted with one or more of the following: a halogen, a C 1 -C 6 alkyl, hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, or a C 1 -C 6 haloalkyl.
- the in the compound of Formula (V) may be at the N-terminus and/or the C-terminus of the compound of Formula (V), adjacent to the N-terminus and/or the C-terminus of the compound of Formula (V), or at a hydrolysis site of the compound of Formula (V).
- the compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III), or Formula (IV) is activated by iodomethane; the coupling is in acetonitrile and comprises addition of DIPEA; and is during a solid phase azapeptide synthesis.
- the compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III) or Formula (IV) is activated by iodomethane, the coupling is in acetonitrile and comprises addition of DIPEA, and is during a liquid phase azapeptide synthesis.
- the azapeptide is preferably prepared in a yield of at least about 40% (by weight) (e.g., from about 45% to about 65%, from about 50% to about 65%, or from about 55% to about 65%, etc.). In certain embodiments, the yield is greater than about 45%, about 50%, about 55%, or about 60%. Thus, the yield may, e.g., be about about 50%, about 55%, about 60%, or about 65%. In certain embodiments, the azapeptide is a di-azapeptide and is synthesized in a yield from about about 80% to about 98%.
- the azapeptide may be prepared in a yield of from about 5% to less than about 40% (e.g., about 36%).
- the invention is also directed in part to a method of preparing a compound of Formula (V), the method comprising a step of coupling a first compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) with an amino acid, a second compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV), a peptide, or an azatide in acetonitrile at a temperature from 15 o C to 35 o C, wherein the coupling is for a time period from about 15 minutes to about 24 hours, from about 15 minutes to about 20 hours, from about 15 minutes to about 18 hours, from about 20 minutes to about 16 hours, from about 20 minutes to about 14 hours, from about 20 minutes to about 12 hours, from about 20 minutes to about 10 hours,
- the coupling is for a time period from about 30 minutes to about 90 minutes at a temperature from about 18 o C to about 25 o C.
- From about 1 to about 3 equivalents of DIPEA and from about 1 equivalents to about 1.4 equivalents (preferally, about 1.1 equivalent) of the amino acid, the second compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV), the peptide, or the azatide may be added to the acetonitrile for the coupling reaction. In some embodiments, no additional reagents are added during the coupling step.
- a compound that is being coupled is an azapeptides with activated carbamoyl imidazole moiety, and about 1.5 eq of an amino acid and about 1.0 eq of DIPEA are used, and the coupling is at room temperature under nitrogen for about 20 hours.
- a compound that is being coupled is an azatide with activated carbamoyl imidazole moiety, and about 1.5 eq hydrazines and about 1.0 eq DIPEA are used, and the coupling is at about 40 o C under nitrogen for about 20 hours.
- a compound that is being coupled is an azapeptide with carbamoyl benzotriazole (HBt) moiety, and about 1.5 eq. of an amino acid and about 2.0 eq. of DIPEA are used, and the coupling is at about 40 o C under nitrogen for about 20 hours.
- a compound that is being coupled is an azapeptide with carbamoyl 1-O-benzotriazole (HOBt) moiety, and about 1.1 eq. of an amino acid and about 2.0 eq DIPEA are used, and the coupling is at about 25 o C under nitrogen for 1 hour.
- the invention is also directed in part to a method of preparing a compound of Formula (V), the method comprising activating a compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III) or Formula (IV) to form an activated compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III), or Formula (IV), and coupling the activated compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III), or Formula (IV) with N-terminal of an amino acid, N-terminal of an aza-mino acid, provided that, if a side chain of the amino acid or aza-amino acid contains a group selected from amino, amide, guanidino N, carboxyl, sulfhydryl, carboxyl, hydroxyl, indole, imidazole phenol, the group is protected with a protecting group
- the invention is further directed in part to a solution phase synthesis of the compounds of Formula (V), the solution phase synthesis comprising a step of converting a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) to an amide of the compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV), a step of deprotectecting the amide of the compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV), a step of coupling the deprotected amide of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) with an additional compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV), or a protected amino acid, or a protected aza-amino acid to form a protected azapeptide, and a step of deprotecting the protected
- the invention is directed in part to a solid phase synthesis of the compounds of Formula (V), the solid phase synthesis comprising a step of coupling a protected compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) to a support, a step of deptrotecting the protected compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV), a step of coupling the deprotected compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) to an additional protected compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV), an additional protected amino acid, or an additional protected aza-amino acid to form a protected peptide, and a step of deprotecting and cleaving the protected peptide to provide a compound of Formula (V).
- the invention is also directed in part to a process of preparing a compound of Formula (V) comprising a step of cleaving a peptide at its N-terminus and/or C-terminus, and a step of coupling the cleaved peptide with a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) to form a compound of Formula (V).
- the compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) is activated prior to the coupling with the cleaved peptide.
- the invention is also directed in part to a process of preparing a compound of Formula (V) comprising a step of cleaving a peptide at its cleavage site to form two smaller peptides, a step of replacing the last amino acid of at least one of the smaller peptides with an aza-amino acid to form an azapeptide, and a step of conjugating the azapeptide with the remaining smaller peptide to provide a compound of Formula (V).
- the invention is also directed in part to a process of preparing a compound of Formula (V) comprising hydrolizing a peptide at its cleavage site, and reacting the cleaved peptide with a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) to provide a compound of Formula (V).
- the invention is further directed in part to a method of azapeptide synthesis comprising reacting a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) with an aza-amino acid, an amino acid, or a peptide to form the azapeptide, wherein the azapeptide is a compound of formula (V).
- the compounds of Formula (I), (IA), (IB), (IC), (II), (III), or (IV) and process of the invention allow, e.g., for preparation of a compound of Formula (V) in yields (% by weight) of at least about 40% (e.g., from about 45% to about 65%, from about 50% to about 65%, or from about 55% to about 65%, etc.).
- the yield is greater than about 45%, about 50%, about 55%, or about 60%.
- the yield may, e.g., be about about 50%, about 55%, about 60%, or about 65%.
- componds of Formula (V) may be prepared in smaller yields (e.g., from about 5% to about 355).
- the invention is further directed in part to prolonging an in vitro and/or in vivo half- life of a peptide, comprising synthesizing a peptidomimetic analogue of the peptide with the compounds of Formula (I), (IA), (IB), (IC), (II), (III) or (IV), the peptidomimetic analogue containing an aza amino acid instead of amino acid at the N-terminus of the peptide, but is otherwise identical to the peptide.
- the peptidomimetic analogue is a compound of Formula (V) or (VI), and is synthesized by liqid phase or solid phase chemistry. In certain embodiments, liquid phase chemistry may be preferred.
- the invention is also directed in part to a process of preparing a compound of Formula (V) comprising cleaving a peptide at its cleavage site to form two smaller peptides, replacing the last amino acid of at least one of the smaller peptides with a compound according to any one of Formulas (I)-(IV) to form an azapeptide, and conjugating the azapeptide with the remaining smaller peptide to provide a compound of Formula (V).
- the invention is also directed in part to a process of preparing a compound of Formula (V) comprising hydrolizing a peptide at its cleavage site, and reacting the cleaved peptide with a compound according to any one of Formulas (I)-(IV) to provide a compound of Formula (V).
- the invention is further directed in part to a method of an azapeptide synthesis comprising reacting a compound according to any one of Formulas (I)-(IV) with an aza-amino acid, an amino acid, a peptide, an azapeptide, or an additional compound according to any one of Formulas (I)-(IV) to form an azapeptide.
- the azapeptide may be, e.g., a compound of Formula (V).
- the invention is further directed in part to a solid phase synthesis of an azapeptide, the solid phase synthesis comprising coupling a compound according to any one of Formulas (I)-(IV) to a support, and coupling an additional protected compound according to any one of Formulas (I)-(IV), an additional protected amino acid, or an additional protected aza-amino acid to the deprotected compound of according to any one of Formulas (I)-(IV).
- the compound according to any one one of Formulas (I)-(IV) may be deprotected prior to said coupling.
- the invention is further directed in part to a solid phase synthesis of an azapeptide, the solid phase synthesis comprising coupling a compound according to any one of Formulas (I)-(IV) to a support, deptrotecting the compound according to any one of Formulas (I)-(XII), and coupling the deprotected compound of according to any one of Formulas (I)-(XII) to a protected compound according to any one of Formulas (I)-(IV), a protected amino acid, or an a protected aza-amino acid.
- the invention is further directed in part to a solution phase synthesis of a compound according to Formula (V), the solution phase synthesis comprising deprotectecting a compound of any one of Formulas (I)-(IV), and coupling the deprotected compound with an additional compound any one of Formulas (I)-(IV), or a protected amino acid, or a protected aza-amino acid to form a protected azapeptide.
- the synthesis may further comprise a step of deprotecting the protected azapeptide to provide a compound of Formula (V).
- the coupling may, e.g., be for a time period of from about 15 minutes to about 12 hours.
- the coupling may be completed in about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, or about 120 minutes.
- the invention is further directed in part to prolonging an in vitro and/or in vivo half- life of a peptide, comprising synthesizing a peptidomimetic analogue of the peptide with the compounds of Formula (I), (IA), (IB), (IC), (II), (III) or (IV), the peptidomimetic analogue containing an aza amino acid instead of amino acid at a position adjacent to the N-terminus of the peptide, but is otherwise identical to the peptide.
- the peptidomimetic analogue is a compound of Formula (V) or (VI), and is synthesized by a liqid phase or a solid phase chemistry.
- the invention is further directed in part to the use of compounds of Formula (V) and Formula (VI) in prevention, diagnosis, inhibition and treatment of medical conditions, including, e.g., cardiovascular disorders, CNS disorders, neurodegenerative disorders, immune system disorders, metabolic disorders, fertility, dental conditions, pain, inflammation, dermatological conditions, blood disorders, infection, eye disorders, gynecologic disorders, urologic disorders, bone and connective tissue disorders, respiratory disorders, gastrointestinal disorders, disorders of endocrine system, and cancer.
- medical conditions including, e.g., cardiovascular disorders, CNS disorders, neurodegenerative disorders, immune system disorders, metabolic disorders, fertility, dental conditions, pain, inflammation, dermatological conditions, blood disorders, infection, eye disorders, gynecologic disorders, urologic disorders, bone and connective tissue disorders, respiratory disorders, gastrointestinal disorders, disorders of endoc
- the methods of diagnosing, prevention and treatment of medical conditions in accordance with the present invention comprise administering a therapeutically effective amount of a compound of Formula (V) or Formula (VI) to a subject in need thereof at specific times in a pharmaceutically acceptable formulation.
- the term “about” in the present specification means a value within 15% ( ⁇ 15 %) of the value recited immediately after the term “about,” including the value equal to the upper limit (i.e., +15%) and the value equal to the lower limit (i.e., -15%) of this range.
- the phrase “about 100” encompasses any numeric value that is between 85 and 115, including 85 and 115.
- An “azapeptide” means a peptide in which one or more ⁇ -carbon(s) are replaced by nitrogen trivalent atom(s).
- An “azatide” means a peptide in which all ⁇ -carbons are replaced by nitrogen trivalent atoms.
- An “aza-amino acid” is defined as an amino acid where the chiral ⁇ -carbon atom is replaced by a nitrogen atom.
- An “ ⁇ -nitrogen” means a nitrogen atom bonded to a carbonyl group in an azapeptide or or an azatide. The carbon atom next to the ⁇ -nitrogen is called the ⁇ -carbon.
- an “azapeptide analogue” means a compound which differs from a peptide that it is an analogue of in that one or more ⁇ -carbon atoms of the peptide have been replaced by a nitrogen atom with or without additional structural modification(s) to the side chain(s) of the amino acid residues of the peptide.
- the one or more ⁇ -carbon atoms that are replaced may, e.g., be at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- the azapeptide analogue preserves, extends and/or improves functional activity of the peptide.
- the azapeptide analogue is more resistant to degradation than the peptide and/or has an improved therapeutic activity than the peptide and/or has an improved selectivity for a biological receptor than the peptide and/or improved affinity to a biological receptor and/or reversed activity at a biological receptor (agonistic activity instead of antagonist activity or antagonistic activity instead of agonistic activity).
- heteroaryl includes all aryl compounds with atoms other than C and H.
- protected means that one or more group(s) (e.g., -OH) in an amino acid, an aza-amino acid, a peptide, an azapeptide, or a compound is protected with a protecting group (e.g., Phth, Ddz, etc.).
- a protecting group e.g., Phth, Ddz, etc.
- protecting group or “protective group,” when used to refer to part of a molecule subjected to a chemical reaction means a chemical moiety that is not reactive under the conditions of that chemical reaction, and which may be removed to provide a moiety that is reactive under those conditions.
- Protecting groups include, for example, nitrogen protecting groups and hydroxy-protecting groups.
- protective group examples include, e.g., benzyl, diphenylmethyl, trityl, Cbz, Boc, Fmoc, methoxycarbonyl, ethoxycarbonyl, Phth, Ddz, as well as other protective groups known to those skilled in the art.
- a “side chain radical” of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R- isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, and glutamine have the following structures:
- a “side chain radical of proline” is a secondary amine, in that the alpha-amino group is attached directly to the main chain, making the ⁇ carbon a direct substituent of the side chain:
- Amino acids which may be used in the present invention are L- and D-amino acids.
- the terms “prevent,” “preventing” and “prevention” contemplate an action that occurs before a patient begins to suffer from the symptoms of specified disease or disorder, which inhibits or reduces the severity of the disease or disorder or of one or more of its symptoms. The terms encompass prophylaxis.
- the compounds of the invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids.
- pharmaceutically acceptable salt[s] generally refers to salts prepared from pharmaceutically acceptable acids or bases including inorganic acids and bases and organic acids and bases.
- suitable pharmaceutically acceptable base addition salts include, e.g., metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from lysine, N,N′-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine.
- Suitable non-toxic acids include inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, formic, fumaric, furoic, galacturonic, gluconic, glucuronic, glutamic, glycolic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phenylacetic, phosphoric, propionic, salicylic, stearic, succinic, sulfanilic, sulfuric, tartaric acid, and p-toluenesulfonic acid.
- inorganic and organic acids such as acetic, alginic, anthranilic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethe
- Specific acids include, e.g., hydrochloric, hydrobromic, phosphoric, sulfuric, and methanesulfonic acids.
- Examples of specific salts include, e.g., hydrochloride and mesylate salts.
- Others are well-known in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing, Easton Pa.: 1990) and Remington: The Science and Practice of Pharmacy, 19th ed. (Mack Publishing, Easton Pa.: 1995).
- compositions of the present invention may also be considered pharmaceutically acceptable if they are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- Such salts may also include various solvates and hydrates of the compound of the present invention.
- Certain compounds of the present invention may be isotopically labelled, e.g., with various isotopes of carbon, fluorine, or iodine, as applicable when the compound in question contains at least one such atom.
- methods of diagnosis of the present invention comprise administration of such an isotopically labelled compound.
- Certain compounds of the present invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom.
- the terms “R” and “S” used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, in Pure Appl. Chem., 1976, 45: 13-30.
- the invention contemplates various stereoisomers and mixtures thereof and these are specifically included within the scope of this invention.
- Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
- Individual stereoisomers of compounds of the invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well known to those of ordinary skill in the art.
- Certain compounds of the present invention may exist as cis- or trans isomers, wherein substituents on a ring may attach in such a manner that they are on the same side of the ring (cis) relative to each other, or on opposite sides of the ring relative to each other (trans). Such methods are well known to those of ordinary skill in the art, and may include separation of isomers by recrystallization or chromatography. It should be understood that the compounds of the invention may possess tautomeric forms, as well as geometric isomers, and that these also constitute an aspect of the invention. [00160] Unless otherwise indicated, a “diagnostically effective amount” of a compound is an amount sufficient to diagnose a disease or condition.
- Phth-protected carbamoyl aza-imidazole derivative of an unnatural amino acid means an unnatural aza-amino acid covalently bound (conjugated) to phthalimidyl at its N-terminus and to imidazole at its C-terminus.
- the unnatural amino acid may be substituted and unsubstituted.
- the term “Phth-protected carbamoyl aza-benzotriazole derivative of an unnatural amino acid” as used herein means means an unnatural aza-amino acid covalently bound (conjugated) to phthalimidyl at its N-terminus and to benzotriazole at its C-terminus.
- the unnatural amino acid may be substituted and unsubstituted.
- solid-phase synthesis means a method in which molecules (e.g., amino acids, aza-amino acids, etc.) are covalently bound on a solid support material and synthesised step-by-step in a single reaction vessel utilising selective protecting group chemistry.
- building blocks are typically protected at all reactive functional groups.
- the order of functional group reactions may be controlled by the order of deprotection.
- an amino-protected amino acid or an amino-protected aza-amino acid is bound to a solid phase material (e.g., low cross-linked polystyrene beads), forming a covalent bond between the carbonyl group and the resin, e.g., an amido or an ester bond.
- the amino group is deprotected and reacted with the carbonyl group of the next amino-protected amino acid or amino-protected aza-amino acid. This cycle is repeated to form the desired peptide or aza-peptide chain.
- solution phase synthesis and “liquid phase synthesis” means a method in which molecules (e.g., amino acids, aza-amino acids, etc.) are synthesized in a solution without being covalently bound on a solid support material.
- sublimin means a building block.
- room temperature means 20°C.
- ambient temperature means 18-28°C.
- parent peptide and “corresponding peptide” mean a native peptide (i.e., natural or convention peptide) that differs from an azapeptide in that one or more of the amino residue(s) of the native peptide is (are) replaced by a semicarbazide or a substituted semicarbazide (i.e., one or more ⁇ -carbon(s) of the native peptide are replaced by nitrogen trivalent atom(s)) in the azapeptide.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C- termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- phthalimidyl means: [00170]
- the term “phthaloyl” means: [00171]
- the abbreviation “N-Phth” means “N-phthalimidyl.”
- the abbreviation “Boc” means “tert-butoxycarbonyl.”
- the abbreviation “Fmoc” means “9-fluorenylmethoxycarbonyl.”
- the abbreviation “Ddz” means “2-(3,5-dimethoxyphenyl)propan-2-yloxycarbonyl.”
- the abbreviation “HOBt” means “1-OH-Benzotriazole.”
- the abbreviation “SPPS” means “Solid Phase Peptide Synthesis.”
- the abbreviation “TCCA” means “trichloroisocyanuric acid.”
- TBACl means “tetrabutyl ammonium chloride.”
- the abbreviation “Aloc” means “allyloxycarbonyl.” [00187] The abbreviation “Mtr” means “methoxytrimethylbenzene sulfonyl.” [00188] The abbreviation “Mbh” means “4,4-dimethyloxybenzhydryl.” [00189] The abbreviation “Pmc” means “2,2,5,7,8-pentamethyl-chroman-6-sulfonyl chloride.” [00190] The abbreviation “Tmob” means 2,4,6-trimethoxybenzyl.
- OAI allyl ester
- Acm acetamidomethyl
- DEAD Diethyl Azodicarboxylate
- IUPAC name N- ethyl-N-propan-2-ylpropan-2-amine IUPAC name N- ethyl-N-propan-2-ylpropan-2-amine.
- deprotection refers to a process of removing the protecting groups (e.g., phthaloyl, Boc, Cbz, Fmoc, etc) by a chemical agent.
- Boc protecting group could be removed under acidic conditions (e.g., 4M HCl, or neat trifluoroacetic acid TFA); Fmoc protecting group could be removed under basic conditions when pH is higher than 12 (20% pipyridine/DMF or DCM); and Phthaloyl group may be cleaved, e.g., under basic conditions or by the use of hydrazine.
- acidic conditions e.g., 4M HCl, or neat trifluoroacetic acid TFA
- Fmoc protecting group could be removed under basic conditions when pH is higher than 12 (20% pipyridine/DMF or DCM)
- Phthaloyl group may be cleaved, e.g., under basic conditions or by the use of hydrazine.
- a replacement of one or more ⁇ -carbon(s) with nitrogen in a peptide converts the peptide to an “azapeptide”; and replacement of all ⁇ -carbon(s) with nitrogen(s) in a peptide converts the peptide to an “azatide.”
- Azapeptides and azatides are peptidomimetics and are generally more resistant to enzymatic hydrolysis than corresponding peptides. The increase in resistance to enzymatic degradation may lead to increased metabolic stability of the compounds and/or an improved receptor binding (e.g., an improved affinity to the receptor).
- azapeptides and azatides are useful tools for drug design, applications in medicinal chemistry, and in diagnosis, prevention and treatment of diseases, and may be used, e.g., instead of peptides, as azapeptide analogues (“peptidomimetics”).
- Compounds of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) of the present invention could be used as “building blocks” or synthons for the synthesis of azapeptides and other peptidomimetics and aza-amino acid conjugates, including compounds of Formula (V) in a solution phase synthesis, a solid phase synthesis or a synthesis comprising both a solution phase synthesis and a solid phase synthesis.
- solution phase synthesis is preferred.
- Preparation of Compounds of Formula (I), (IA), (IB), (IC), (II), (III) and (IV) [00198] Compounds of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) may be prepared, e.g., by the methods described in U.S. Serial No.16/869,692, filed on May 8, 2020, U.S. Serial No.16/869,749, filed on May 8, 2020, and U.S. Serial No.16/869,794, filed on May 8, 2020, all three hereby incorporated by reference in their entireties.
- Compounds of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) can also be used, e.g., as sub-units to elongate and/or cap peptides and azapeptides.
- compounds of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) may be activated by iodomethane, and the activated compound may be coupled, e.g., a protected or unprotected aza-amino acid; a protected or unprotected peptide; a protected or unprotected azapeptide; a protected or unprotected azatide; or a protected or unprotected compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III), or Formula (IV); or a protected or unprotected hydrazine, by either solution or liquid phase synthetic methodologies, e.g., to form a compound of Formula (V).
- the amino acid, the aza-amino acid, the peptide, the azapeptide, compound of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) may each be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 -C 6 alkyl (e.g., methyl), hydroxyl, -COOH, - COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.).
- the coupling may, e.g., be for up to about 20 hours.
- the coupling may be completed in about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, or about 120 minutes.
- compounds of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) may be activated by methylation of imidazole residue using MeI, and the activated compound may be coupled, e.g., a protected or unprotected aza-amino acid; a protected or unprotected a peptide; a protected or unprotected azapeptide; a protected or unprotected azatide; or a protected or unprotected compound of Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (II), Formula (III), or Formula (IV); or a protected or unprotected hydrazine, by either solution or liquid phase synthetic methodologies, e.g., to form
- the amino acid, the aza-amino acid, the peptide, the azapeptide, compound of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) may each be unsubstituted or substituted with one or more of the following: a halogen (Cl, F, or Br), a C 1 - C 6 alkyl (e.g., methyl), hydroxyl, -COOH, -COH, methoxyl, ethoxyl, propoxyl, a C 1 -C 6 haloalkyl (e.g., a chloromethyl, a fluromethyl, etc.).
- a halogen Cl, F, or Br
- a C 1 - C 6 alkyl e.g., methyl
- hydroxyl, -COOH, -COH methoxyl, ethoxyl, propoxyl
- a C 1 -C 6 haloalkyl e.
- the methylation of imidazole residue could, e.g., in acetonitrile at 25 o C under nitrogen for 20 hours.
- the methods of the invention may be used to synthesize azapeptides and azatides from 3 to 200 mers in length, e.g., tri-azatides, tetra-azapeptides, penta-azapeptides, etc. In certain embodiments, the peptide is 9 mers in length.
- the method of preparing an azapeptide or an azatide comprises hydrolysing a peptide, e.g., a compound of Formula (VI) into fragments and reacting one or more fragments with a compound of Formula (I), (IA),(IB), (IC), (II), (III), or (VI).
- the method of preparing an azapeptide or an azatide comprises cleaving a peptide, e.g., a compound of Formula (VI), into fragments and reacting one or more fragments with a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (VI).
- the method of preparing an azapeptide or an azatide comprises cleaving an end of a peptide, e.g., a compound of Formula (IV), and reacting the cleaved peptide with a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (VI).
- the method of preparing an azapeptide or an azatide comprises reacting a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (VI) with a truncated peptide.
- the method of preparing an azapeptide or an azatide comprises conjugating a compound of Formula (I), (IA), (IB), (IC), (II), (III), or (VI) with a truncated peptide, e.g., a compound of Formula (V).
- a method of azapeptide or azatide synthesis comprises reacting (i) a benzotriazole derivative of an aza-amino acid comprising an aza-amino acid covalently bound (conjugated) to a protecting group at its N-terminus and to benzotriazole at its C-terminus with (ii) a peptide to form the azapeptide or azatide, wherein the benzotriazole derivative of the aza-amino acid azapeptide or azatide is a compound of Formula (I), (IA), (IB), (IC), (II) or (III).
- a method of azapeptide or azatide synthesis comprises reacting (i) an imidazole derivative of an aza-amino acid comprising an aza-amino acid covalently bound (conjugated) to a protecting group at its N-terminus and to imidazole at its C-terminus, wherein the aza-amino acid is selected from the group consisting of aza-glycine, aza-alanine, aza-valine, aza-leucine, aza-isoleucine, aza-proline, aza-phenylalanine, aza- tyrosine, aza-tryptophan, aza-aspartic acid, aza-glutamic acid, aza-aspargine, aza-glutamine, aza-histidine, aza-lysine, and aza-arginine with (ii) a hydrazide to form an azapeptide.
- the imidazole derivatve is a compound of Formula (I).
- Compounds of Formula (I), (IA), (IB), (IC), (II), (III), and (IV) may be used in the methods of azapeptide and azatide synthetheses described in U.S. Serial No.16/869,692, filed on May 8, 2020, U.S. Serial No.16/869,749, filed on May 8, 2020, and U.S. Serial No. 16/869,794, filed on May 8, 2020, in preparation of azapeptides and other peptidomimetic agents, instead of or with the building blocks described in these applications.
- Compounds of Formula (V) are azapeptide analogues of compounds of Formula (VI). In the preferred embodiments, compounds of Formula (V) are more resistant to hydrolysis and/or enzymatic degradation than compounds of Formula (VI). [00213] Componds of Formula (V) may be used to inhibit peptidases, both in vitro and in vivo.
- the peptidase may, e.g., be an endopeptidase, an exopeptidase, an aspartic protease, a glutamic protease, an asparagine peptide lyase, or a retroviral protease.
- compounds of Formula (V) are more potent than compounds of Formula (VI), e.g., due to a better fit into a biological receptor.
- Compounds of Formula (V) could be used, e.g., in drug discovery, diagnosis, prevention, inhibition, and treatment of diseases.
- Compounds of Formulas (V) may each comprise from 3 to 200 carbonyl group(s).
- compounds of Formula (V) may each comprise 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 41, 43, 44, 56, or 166 carbonyl groups.
- compounds of Formula (V) comprise from 3 to 60 carbonyl groups, from 3 to 50 carbonyl groups, from 3 to 40 carbonyl groups, from 3 to 30 carbonyl groups, from 3 to 25 carbonyl groups, from 3 to 20 carbonyl groups, from 3 to 15 carbonyl groups, from 3 to 12 carbonyl groups, from 3 to 10 carbonyl groups, from 3 to 9 carbonyl groups, from 4 to 40 carbonyl groups, from 4 to 30 carbonyl groups, from 4 to 25 carbonyl groups, from 4 to 20 carbonyl groups, from 4 to 15 carbonyl groups, from 4 to 12 carbonyl groups, from 4 to 10 carbonyl groups, or from 4 to 9 carbonyl groups.
- compounds of Formula (V) comprise from 3 to 200 carbonyl groups and at least one ⁇ -nitrogen covalently bound to at least one of said carbonyl groups, and have a greater bioavailability (e.g., oral, transdermal, and/or intranasal) than a peptide structurally different from the compounds of Formula (V) only in that that the peptide comprises ⁇ -carbon instead of said ⁇ -nitrogen.
- the ⁇ -nitrogen is at the N-termini or C-termini of the compounds of Formula (V).
- the ⁇ - nitrogen is at the N-termini and the C-termini of the compounds of Formula (V).
- the ⁇ -nitrogen is not at the N-termini and not at the C-termini of the compounds of Formula (V), rather it is at a cleavage or hydrolysis site(s) of the peptide.
- compounds of Formula (V) are azapeptide analogues of therapeutic peptides.
- compounds of Formula (V) are azapeptide analogues of diagnostic peptides.
- Compounds of Formula (V) may be used in drug discovery, diagnosis, prevention, inhibition, and treatment of diseases.
- compounds of Formula (V) comprise a backbone comprising from 2 to 200 carbonyl groups and ⁇ -nitrogen covalently bound to at least one of said carbonyl groups, and are therapeutically effective for the treatment of a disorder in a subject, while a peptide structurally different from the compounds of Formula (V) only in that that the peptide comprises ⁇ -carbon instead of said ⁇ -nitrogen is not therapeutically effective for the treatment of the disorder.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprise from 3 to 200 carbonyl groups and ⁇ -nitrogen covalently bound to at least one of said carbonyl groups, and have a therapeutic efficacy greater than a peptide structurally different from the compounds of Formula (V) only in that the peptide comprises an ⁇ -carbon instead of said ⁇ -nitrogen.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprise from 3 to 200 carbonyl groups and ⁇ -nitrogen covalently bound to at least one of said carbonyl groups, and have a longer duration of therapeutic activity than a peptide structurally different from the compounds of Formula (V) only in that that the peptide comprises ⁇ -carbon instead of said ⁇ - nitrogen.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprise from 3 to 75 carbonyl groups and at least one ⁇ -nitrogen covalently bound to at least one of said carbonyl groups, and have an in vivo half-life greater than a peptide structurally different from the compounds of Formula (V) only in that said at least one ⁇ -nitrogen is replaced with ⁇ -carbon.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprise a backbone comprising from 2 to 75 carbonyl groups, wherein at least two carbonyl groups are covalently bound to a trivalent nitrogen, and compounds of Formula (V) have an in vivo half-life greater than a peptide structurally different from the compounds of Formula (V) only in that one or more alpha nitrogen(s) of the compounds of Formula (V) is replaced with alpha carbon(s).
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprise at least one aza-amino acid, and have an in vivo half-life greater than a peptide structurally different from the compounds of Formula (V) only in that the aza-amino acid(s) is replaced with a corresponding amino acid.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprise from 3 to 200 carbonyl groups and ⁇ -nitrogen covalently bound to at least one of said carbonyl groups, and are more resistant to protease degradation than a peptide structurally different from the compounds of Formula (V) only in that that the peptide comprises ⁇ -carbon instead of said ⁇ -nitrogen.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprise from 3 to 200 carbonyl groups and ⁇ -nitrogen covalently bound to at least one of said carbonyl groups, and have a greater affinity to a biological receptor than a peptide structurally different from the compounds of Formula (V) only in that that the peptide comprises ⁇ -carbon instead of said ⁇ - nitrogen.
- the replacement may be, e.g., at the N-termini of the peptide (i.e., the first residue of the peptide), at the second residue of the peptide, the C-termini of the peptide (i.e., the last residue of the peptide), the residue covalently bound to the C-termini of the peptide, and/or at another residue of the peptide (e.g., at the site of hydrolysis of the peptide).
- compounds of Formula (V) comprises from 3 to 60 carbonyl groups.
- compounds of Formula (V) are linear.
- compounds of Formula (V) are cyclic.
- compounds of Formula (V) are pegylated. [00232] In certain embodiments, compounds of Formula (V) are conjugated to an immunoglobulin. [00233] In certain embodiments, compounds of Formula (V) comprise ⁇ -nitrogen at the N- terminus of its backbone. [00234] In certain embodiments, compounds of Formula (V) comprise ⁇ -nitrogen at the C- terminus of its backbone [00235] In certain embodiments, compounds of Formula (V) comprise two carbonyl groups and two ⁇ -nitrogens. [00236] In certain embodiments, compounds of Formula (V) comprise three carbonyl groups and one ⁇ -nitrogen.
- compounds of Formula (V) comprise three carbonyl groups and two ⁇ -nitrogens. [00238] In certain embodiments, compounds of Formula (V) comprise three carbonyl groups and three ⁇ -nitrogens. [00239] In certain embodiments, compounds of Formula (V) comprise four carbonyl groups and one ⁇ -nitrogen. [00240] In certain embodiments, compounds of Formula (V) comprise four carbonyl groups and two ⁇ -nitrogens. [00241] In certain embodiments, compounds of Formula (V) comprise four carbonyl groups and three ⁇ -nitrogens. [00242] In certain embodiments, compounds of Formula (V) comprise four carbonyl groups and four ⁇ -nitrogens.
- compounds of Formula (V) are azapeptide analogues of a 3 to 200 amino acid peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza- analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 3 to 200 amino acid peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine, wherein the analogue includes at least one corresponding aza-amino acid of the amino acid.
- compounds of Formula (V) are azapeptide analogues of a 3 to 200 amino acid peptide, the 3 to 200 amino acid peptide comprising amino acids selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, arginine, the analogue differing from the amino acid peptide in that that the aza-analogues comprise an aza-amino acid instead of at least one of the amino acids, wherein the aza-analogues comprise aza-glycine instead of glycine, and/or the aza-analogues comprise aza-alanine instead of alanine, and/or the aza-analogues comprise aza-valine instead of valine, and/or the aza-an
- compounds of Formula (V) are azapeptide analogues of a peptide comprising from 3 to 50 amino acids selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, arginine, and at least 3, 4, 5, 6, 7, 8, 9 or 10 of the amino acids are replaced with corresponding aza-amino acids.
- the replaced amino acid is the first amino acid of the peptide.
- compounds of Formula (V) are azapeptide analogues of a 10-mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 9- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 8- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 7- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 6- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 5- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 5- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 4- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 3- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- compounds of Formula (V) are azapeptide analogues of a 3- mer peptide comprising an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, aspartic acid, glutamic acid, aspargine, glutamine, histidine, lysine, and arginine; the aza-analogues differing from the amino acid peptide in that that the amino acid of the peptide is replaced with a corresponding aza-amino acid.
- the last amino acid of the peptide is selected from the group consisting of aspartic acid, phenylalanine, and arginine.
- the first amino acid of the peptide is selected from the group consisting of tyrosine, phenylalanine, and arginine.
- the first and the last amino acid of the peptide are the same.
- the first and the last amino acids of the peptide are different.
- compounds of Formula (V) are not azatides.
- compounds of Formula (V) comprise an amino acid selected from the group consisting of cysteine, methionine, serine and threonine.
- compounds of Formula (V) comprise at least one, at least two or at least three aza-glycine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-alanine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-valine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-leucine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-isoleucine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-proline(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-phenylalanine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-tyrosine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-tryptophan(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-aspartic acid(s). [00273] In certain embodiments, compounds of Formula (V) comprise at least one, at least two or at least three aza-glutamic acid(s). [00274] In certain embodiments, compounds of Formula (V) comprise at least one, at least two or at least three aza-aspargine(s). [00275] In certain embodiments, compounds of Formula (V) comprise at least one, at least two or at least three aza-glutamine(s). [00276] In certain embodiments, compounds of Formula (V) comprise at least one, at least two or at least three aza-histidine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-lysine(s).
- compounds of Formula (V) comprise at least one, at least two or at least three aza-arginine(s).
- compounds of Formula (V) comprise aza-glycine, aza- alanine, aza-valine, aza-leucine, aza-isoleucine, aza-proline, aza-phenylalanine, aza-tyrosine, aza-tryptophan, aza-aspartic acid, aza-glutamic acid, aza-aspargine, aza-glutamine, aza- histidine, aza-lysine, or aza-arginine on their N-termini and/or C-termini.
- compounds of Formula (V) comprise aza-glycine, aza- alanine, aza-valine, aza-leucine, aza-isoleucine, aza-proline, aza-phenylalanine, aza-tyrosine, aza-tryptophan, aza-aspartic acid, aza-glutamic acid, aza-aspargine, aza-glutamine, aza- histidine, aza-lysine, or aza-arginine on their N-termini and/or C-termini, and are aza- analogues of a therapeutic peptide, and have a greater bioavailability (e.g., oral, transdermal, and/or intranasal) than the therapeutic peptide (in its unaltered state).
- a greater bioavailability e.g., oral, transdermal, and/or intranasal
- compounds of Formula (V) comprise aza-glycine, aza- alanine, aza-valine, aza-leucine, aza-isoleucine, aza-proline, aza-phenylalanine, aza-tyrosine, aza-tryptophan, aza-aspartic acid, aza-glutamic acid, aza-aspargine, aza-glutamine, aza- histidine, aza-lysine, or aza-arginine on their N-termini and/or C-termini, and are aza- analogues of a therapeutic peptide, maintain the therapeutic efficacy of the therapeutic peptide and have an in vivo half-life greater than the in vivo half-life of the therapeutic peptide.
- compounds of Formula (V) comprise aza-glycine, aza- alanine, aza-valine, aza-leucine, aza-isoleucine, aza-proline, aza-phenylalanine, aza-tyrosine, aza-tryptophan, aza-aspartic acid, aza-glutamic acid, aza-aspargine, aza-glutamine, aza- histidine, aza-lysine, or aza-arginine on their N-termini and/or C-termini, are aza-analogues of a therapeutic peptide and have a longer duration of therapeutic activity than the therapeutic peptide.
- compounds of Formula (V) comprise aza-glycine, aza- alanine, aza-valine, aza-leucine, aza-isoleucine, aza-proline, aza-phenylalanine, aza-tyrosine, aza-tryptophan, aza-aspartic acid, aza-glutamic acid, aza-aspargine, aza-glutamine, aza- histidine, aza-lysine, or aza-arginine on their N-termini and/or C-termini, are aza-analogues of a therapeutic peptide and are more resistant to protease degradation than the therapeutic peptide.
- compounds of Formula (V) comprise aza-glycine, aza- alanine, aza-valine, aza-leucine, aza-isoleucine, aza-proline, aza-phenylalanine, aza-tyrosine, aza-tryptophan, aza-aspartic acid, aza-glutamic acid, aza-aspargine, aza-glutamine, aza- histidine, aza-lysine, or aza-arginine on their N-termini and/or C-termini, are aza-analogues of a therapeutic peptide and have a greater affinity to a biological receptor than the therapeutic peptide.
- a compound of Formula (V) is a tri-azatide of Formula (X): or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of unsubstituted and substituted side chain radicals of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R-isoleucine, S-isoleucine and RS-isoleucine), arginine, glycine, asparagine, proline, and glutamine.
- R is selected from the group consisting of unsubstituted and substituted side chain radicals of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine (including, R-isoleu
- the tri-azatides may, e.g., be prepared by a solution phase or a solid phase synthesis. [00287] The tri-azatides may be prepared both with C-to-N terminal construction and N-to-C terminal construction. Tetra-Azapeptides [00288] In certain embodiments, a compound of Formula (V) is a compound of formula:
- a compound of Formula (V) is a compound of formula: or a pharmaceutically acceptable salt thereof.
- the tetra-azatides may, e.g., be prepared by a solution phase or a solid phase synthesis.
- the tetra-azatides may be prepared both with C-to-N terminal construction and N-to- C terminal construction.
- Nine-mer Azapeptides [00292] In certain embodiments, a compound of Formula (V) is a compound of formula:
- a compound of Formula (V) is a compound of formula: or a pharmaceutically acceptable salt thereof.
- a compound of Formula (V) is a compound of formula: or a pharmaceutically acceptable salt thereof.
- a compound of Formula (V) is a compound of formula: or a pharmaceutically acceptable salt thereof.
- a compound of Formula (V) is a compound of formula: or a pharmaceutically acceptable salt thereof.
- the nine- mer azapeptides may, e.g., be prepared by a solution phase, a solid phase synthesis and a combination of the solution and solid phase synthesis. [00298] The nine- mer azapeptides may be prepared both with C-to-N terminal construction and N-to-C terminal construction.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of A-6, A-623 (AMG-623), A-71378, A-75998, Abarelix (PPI- 149), ABT-510, AC-100, AC-162352 (PYY 3-36), AC-253, AC-2592, AC-625, ACV-1, ADH-1, AEZS-108 (AN-152) (ZEN-008), AF-37702, Afamelanotide (EP-1647) (CUV-1647) (Melanotan I), AG2/102, AG-284, AI-502, AKL-0707 (LAB GHRH), Albiglutide (GSK- 716155), Albuvirtide, ALG-889, Alloferon, Allotrap 2702 (B-2702), ALTY-0601, ALX-40- 4C, Ambamustine (PTT-119), Anaritide, Antagonist G (PTL-68001),
- compounds of Formula (V) are selected from the group consisting of aza-analogues of AC-2592, AC-625, Anaritide, APL-180, Atriopeptin, BGC- 728, Carperitide (SUN-4936), CD-NP, CG-77X56, D-4F (APP-018), Danegaptide (ZP-1609) (WAY-261134) (GAP-134), DMP-728 (DU-728), Efegatran (LY-294468), EMD-73495, Eptifibatide (C68-22), ET-642 (RLT-peptide), FE 202158, FX-06, Icatibant (JE-049) (HOE- 140), lcrocaptide (ITF-1697), KAI-1455, KM-9803, L-346670, L-364343, LSI-518P, Nesiritide, Peptide renin inhibitor, PL-3994, Rotigaptide (ZP
- compounds of Formula (V) are selected from the group consisting of aza-analogues of Azetirelin (YM-14673), Conantokin G, Corticorelin (NEU- 3002), CTS-21166 (ASP-1702) (ATG-Z1) (OM-00-3) (OM-99-2), Davunetide (AL-108) (AL-208), Deltibant (CP-0127), Ebiratide (Hoe-427), FGLL, Glypromate, JTP-2942, MontireIin (CG-3703), Nemifitide (INN-00835), NNZ-2566, NT-13, ORG-2766, Peptide T (AIDS000530), Posatirelin, PPI-1019, Protirelin, Secretin (human) (RG-1068), SGS-111 , Taltirelin (TA-0910), XG-102, or Ziconotide (SNX-111), and have utility in the treatment of CNS disorders (e
- compounds of Formula (V) are selected from the grouop consisting of aza-analogues of A-6, Abarelix (PPI-149), ABT-510, ADH-1, AEZS-108 (AN- 152) (ZEN-008), Ambamustine (PTT-119), Antagonist G (PTL-68001), ATN-161, Avorelin (EP-23904), Buserelin, Carfilzomib (PR-171), CBP-501, Cemadotin (LU-103793), Chlorotoxin (TM-601), Cilengitide (EMD-121974) (EMD-85189), CTCE-9908, CVX-045, CVX-060, Degarelix (FE 200486), Didemnin B (NSC-325319), DRF-7295, Edotreotide (SMT-487), Elisidepsin (PM-02734), EP-100, Glutoxim (NOV-002),
- compounds of Formula (V) are selected from the group consisting of aza-analogues of A-623 (AMG-623), AG-284, AI-502, Allotrap 2702 (B-2702), AZD-2315, Cnsnqic-Cyclic (802-2), Delmitide (RDP-58), Dirucotide (MBP-8298) Disitertide (NAFB-001) (P-144), dnaJP1 (AT-001), Edratide (TV-4710), F-991, FAR-404, Glaspimod (SKF-107647), Glatiramer (COP-1), GMDP, IPP-201101, Icatibant (JE 049)(HOE-140), MS peptide, Org-42982 (AG-4263), Pentigetide(TA-521), PI-0824, PI-2301, PLD-116, PMX-53, PTL-0901, RA peptide, TCMP-80, Thymode
- compounds of Formula (V) are selected from the group consisting of aza-analogues of A-71378, AC-162352 (PYY 3-36), AC-253, AG2/102, AKL- 0707 (LAB GHRH), Albiglutide (GSK-716155), AOD-9604, BAY-73-7977, BIM-44002, BMS-686117, BRX-0585, CJC-1131 (DAC:GLP-1), CJC-1134 (PC-DAC) (Exendin-4), CJC-1295 (DAC:GRF), CP-95253, CVX-096 (PF-4856883), Davalintide (AC-2307), Exenatide (AC-2993) (LY-2148568), Exsulin (INGAP Peptide), Glucagon, ISF402, Liraglutide (NN-2211), Lixisenatide (AVE-0010) (ZP-10), LY-2189265, LY-548806, nafarelin
- compounds of Formula (V) are selected from the group consisting of aza-analogues of A-75998, Buserelin, Cetrorelix (NS-75), Detirelix (RS-68439), Ganirelix (Org-37462) (RS-26306), Iturelix, Nafarelin (RS-94991), or triproletin (WY- 42462); and have utility in the treatment of fertility.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of AC-100 and p-1025, and have utility in the treatment of dental disorders.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of ACV-1, Conantokin G, CJC-1008 (DAC: Dynorphin A), Contulakin G (CGX-1007), CR-665, CR-845, Dynorphin A, E-2078, Felypressin, Frakefamide (LEF-576) (SPD-759) (BCH-3963), HP-228, Icatibant (JE-049) (HOE-140), KAI-1678, Leconotide (AM-336), Metkephamide (LY-127623), MPL-TLB100, NT-13, SYN-1002, TX14(A), Xen-2174, and Ziconotide (SNX-111); and have utility in the treatment of pain.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of Afamelanotide (EP-1647) (CUV-1647) (Melanotan I), AZX- 100, DPK-060, DSC-127, Hemoparatide (PTH( 1-37)), Hexapeptide copper II (PC-1358), Pexiganan (MSI-78), PTH (7-34), PXL-01, SKF-110679 (U-75799E), or Thymosin beta-4; and have utility in the treatment of dermatologic conditions (e.g., alleviate one or more symptom(s) of a dermatologic condition).
- dermatologic conditions e.g., alleviate one or more symptom(s) of a dermatologic condition.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of AF-37702, Bivalirudin (BG-8865), carfilomib, (PR-171), CTCE-0214, ETRX 101, H-142, OGP 10-14L, Ornithine vasopressin, peg-TPOmp (RWJ- 800088), R-1516, Romiplostim (AMG-531), and TP-9201; and have utility in the treatment of hematology disorders (e.g., alleviate one or more symptom(s) of a hematology disorder).
- compounds of Formula (V) are selected from the group consisting of aza-analogues of Albuvirtide, ALG-889, Alloferon, ALX-40-4C, CB-182804, CB-183315, CZEN-002, Enfuvirtide (T-20), Glucosamyl muramyl tripeptide, Golotimod (SCV-07), GPG-NH2, hLF(1-11), IMX-942, Iseganan (IB-367), Murabutide (VA-101) (CY- 220), Neogen, NP-213, Oglufanide (IM-862), Omiganan (CPI-226), OP-145, p-1025, P-113 (PAC-113), Pep-F (5K), R-15-K, Sifuvirtide, SPC-3, Thymalfasin, Thymonoctan (FCE- 25388), Tifuvirtide (R-724) (T-1249), TRI
- compounds of Formula (V) are selected from the group consisting of aza-analogues of ALTY-0601, B27PD, BDM-E, BIM-23190, CBT-101, Compstatin (POT—4), Eledoisin (ELD-950), and LYN-001, and have utility in the treatment of ophthalmologic disorders.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of Atosiban (ORF-22164), Barusiban (FE-200400), Carbetocin, Cargutocin (Y-5350), Deslorelin, Oxytocin, or TT-235, and have utility in the treatment of OB-GYN disorders.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of Aviptadil (PSD-510), Bremelanotide (PT-141), C-peptide (SPM-933), Desmopressin, EA-230, Lypressin, MER-104, MT-ll (PT-14), SKF-101926, or Vasopressin, and have utility in the treatment of urologic conditions (e.g., alleviate one or more symptom(s) of a urologic condition).
- urologic conditions e.g., alleviate one or more symptom(s) of a urologic condition.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of AC-100, BA-058, Calcitonin (Human), Calcitonin (Salmon), Elcatonin, I-040302 (KUR-112), PTHrP-(1-36), Rusalatide (TP-508), SAN-134, Teriparatide (LY-333334), or ZT031; and have utility in the treatment of bones and connective tissue disorders.
- compounds of Formula (V) are selected from the group consisting of aza-analogues of BIO-1211, CGRP (LAB-CGRP), Glucosamyl muramyl tripeptide, GMDP, Icrocaptide (ITF-1697), Lucinactant, Lusupultide (BY-2001), NPC-567, NPY (24-36) (PTL-041120), or Secretin (human) (PGN-52) (R-52); and have utility in the treatment of respiratory conditions (e.g., alleviate one or more symptom(s) of a respiratory condition).
- compounds of Formula (V) are selected from the group consisting of aza-analogues of Casokefamide, CCK (25-33), Lagatide (BN-52080), Larazotide (AT-1001) (SPD-550), Linaclotide (MD-1100) (MM-41775), Nepadutant (MEN- 11420), Nifalatide (BW942C), ROSE-010 (GTP-010) (LY-307161), Somatostatin, Somatostatin (D-Trp, D-Cys analog), SP-304 (Guanilib), Teduglutide(ALX-0600), Terlipressin, Triletide (Z-420) (ZAMI-420), Vapreotide (RC-160), ZP-1846, or ZP-1846; and have utility in the treatment of gastroenterologic disorders (e.g., alleviate one or more symptom(s) of a gastroenterologic disorder).
- gastroenterologic disorders e.g., alleviate one or more
- compounds of Formula (V) are selected from the group consisting of aza-analogues of CJC-1295 (DAC:GRF), DG-3173 (PTR-3173), Dopastatin (BIM-23A760), EP-51216 (EP-51389), Examorelin (EP-23905) (MF-6003), GTP -200 (GTP- 300), lpamorelin (NNC-26-0161), Iturelix (ORF-23541), KP-101 (GHRP-1), Lanreotide (ITM-014), Octreotide (SMS-201-995), Pasireotide (SOM-230), Pralmorelin, rGRF, SUN- 11031, TH-9506, ZT0131, or vapreotide (RC-160); and have utility in the treatment of endocrinology disorders (e.g., alleviate one or more symptom(s) of a gastroenterologic disorder).
- endocrinology disorders e.g., alleviate
- Example 2 [00320] tert-butyl 2-(2-benzyl-2-((ethylthio)carbonyl)hydrazine-1-carbonyl)pyrrolidine-1- carboxylate: [BocProAzaPhe(SEt) (A9065-2)]: [00321] To a solution of thiocarbazate 2 (304 mg, 1.45 mmol) in DMF (8.0 mL) was added N-Boc Proline (343 mg, 1.59 mmol), HATU (722.4 mg, 1.59 mmol), HOBt (214 mg, 1.59 mmol), and M-methyl morpholine (650 uL, 6.4 mmol).
- the reaction was stopped after one hour by adding 20 mL of saturated ammonium chloride; the aqueous layer was transferred to a separatory funnel and extracted with EtOAc (20 mL X 3). The combined organic layer was washed with water (20 mLx3), dried over sodium sulfate, filtered, and evaporated to dryness. The crude material was eluted quickly through a silica gel pad to remove the unreacted t-Bu carbazate and the Fmoc Proline amino acid. Half of the resulting semicarbazate (7.4 mmol) was dissolved in DCM (5.0 mL) and treated at 0 °C with TFA (5.0 mL).
- reaction mixture was stirred at 0 °C and warmed up gradually for 30 min. Later the excess solvent was removed under vacuum, and the resulting material was dissolved in DCM (5.0 mL) and THF (10.0 mL). To the reaction mixture was added benzaldehyde (1.0 mL, ten mmol) and anhydrous MgSO 4 (2.0 g). The reaction mixture was heated to reflux and stirred at 60 °C for 30 min; then it was filtered over a celite pad; the filtrate was evaporated to dryness and redissolved in DCM (20 mL).
- the reaction mixture was placed in an ice/acetone bath (-6 C) and treated with BH 3 .NMe 2 (928 mg, 16 mmol) and PTSA (11.5 g, 60 mmol).
- the PTSA was dissolved in a 3:1 ratio of DCM/MeOH (18 mL) and introduced slowly in a portion-wise manner.
- the reaction was stopped after 30 min by adding slowly at 0 °C 10% Na 2 CO 3 solution (50 mL). When the gas completely ceased off.
- the mixture was heated to reflux for another 30 min at 60 °C.
- the aqueous layer was extracted with DCM (20 mL X3).
- the solution was placed in an ice bath and treated with BH 3 .Me 2 (460 mg, 8.0 mmol) and PTSA (3.8 g, 20.0 mmol).
- the PTSA was dissolved in a 3:1 ratio of DCM/MeOH (18 mL) and introduced slowly in a portion-wise manner. The reaction was stopped after 30 min by adding slowly at 0 °C 10% Na 2 CO 3 solution (50 mL). When the gas completely ceased off. The mixture was heated to reflux (40 C) for another 30 min at 60 °C.
- the aqueous layer was extracted with DCM (20 mL X3). The organic layer was washed successively with brine and water, dried over Na 2 SO 4 , filtered, and evaporated to dryness.
- the filtrate was concentrated under vacuum and redissolved in DCM (10.0 mL).
- the solution was placed in an ice bath and treated with BH 3 .Me 2 (278 mg, 4.8 mmol) and PTSA (2.9 g, 15 mmol).
- the PTSA was dissolved in a 3:1 ratio of DCM/MeOH (9.0 mL) and introduced slowly in a portion-wise manner.
- the reaction was stopped after 30 min by adding slowly at 0 °C 10% Na 2 CO 3 solution (50 mL). When the gas completely ceased off, the mixture was heated to reflux (40 °C) for another 30 min at 60 °C.
- the aqueous layer was extracted with DCM (20 mL X3).
- Example 7 [00331] BocProPhePhe(StBu) was prepared by solution phase synthesis utilizing BocProPhe(SeEt). The following synthetic scheme was used: [00332] To a solution of A9065 (41 mg, 0.1 mmol) in DCM (0.5 mL) was added TBACl (28 mg, 0.1 mmol) and TCCA (23 mg, 0.1 mmol). The reaction was stirred at room temperature vigorously for 5 min; then, it was treated with t-butyl phenylalanine ester (39 mg, 0.15 mmol) and Et3N (55 uL, 0.4 mmol). Then, the reaction mixture was stirred at room temperature for an additional hour.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21800750.8A EP4146629A1 (en) | 2020-05-08 | 2021-05-07 | Dimers for use in synthesis of peptidomimetics |
CN202180032654.0A CN115515937A (en) | 2020-05-08 | 2021-05-07 | Dimers for the synthesis of peptidomimetics |
AU2021267384A AU2021267384A1 (en) | 2020-05-08 | 2021-05-07 | Dimers for use in synthesis of peptidomimetics |
US17/922,945 US20230159450A1 (en) | 2020-05-08 | 2021-05-07 | Dimers for use in synthesis of peptidomimetics |
CA3174239A CA3174239A1 (en) | 2020-05-08 | 2021-05-07 | Dimers for use in synthesis of peptidomimetics |
IL297452A IL297452A (en) | 2020-05-08 | 2022-10-19 | Dimers for use in synthesis of peptidomimetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063021803P | 2020-05-08 | 2020-05-08 | |
US63/021,803 | 2020-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021226431A1 true WO2021226431A1 (en) | 2021-11-11 |
Family
ID=78468419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/031246 WO2021226431A1 (en) | 2020-05-08 | 2021-05-07 | Dimers for use in synthesis of peptidomimetics |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230159450A1 (en) |
EP (1) | EP4146629A1 (en) |
CN (1) | CN115515937A (en) |
AU (1) | AU2021267384A1 (en) |
CA (1) | CA3174239A1 (en) |
IL (1) | IL297452A (en) |
WO (1) | WO2021226431A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646276A (en) * | 1992-05-13 | 1997-07-08 | Bristol-Myers Squibb Co. | Diazepine containing dual action inhibitors |
KR20050099732A (en) * | 2004-04-12 | 2005-10-17 | 한국화학연구원 | Pyrazolidine derivatives comprising urea group or pharmaceutical acceptable salts thereof and the preparation thereof |
WO2019007383A1 (en) * | 2017-07-05 | 2019-01-10 | 凯惠科技发展(上海)有限公司 | Peptide compound and application thereof, and composition containing peptide compound |
-
2021
- 2021-05-07 WO PCT/US2021/031246 patent/WO2021226431A1/en unknown
- 2021-05-07 CN CN202180032654.0A patent/CN115515937A/en active Pending
- 2021-05-07 US US17/922,945 patent/US20230159450A1/en active Pending
- 2021-05-07 AU AU2021267384A patent/AU2021267384A1/en active Pending
- 2021-05-07 CA CA3174239A patent/CA3174239A1/en active Pending
- 2021-05-07 EP EP21800750.8A patent/EP4146629A1/en active Pending
-
2022
- 2022-10-19 IL IL297452A patent/IL297452A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5646276A (en) * | 1992-05-13 | 1997-07-08 | Bristol-Myers Squibb Co. | Diazepine containing dual action inhibitors |
KR20050099732A (en) * | 2004-04-12 | 2005-10-17 | 한국화학연구원 | Pyrazolidine derivatives comprising urea group or pharmaceutical acceptable salts thereof and the preparation thereof |
WO2019007383A1 (en) * | 2017-07-05 | 2019-01-10 | 凯惠科技发展(上海)有限公司 | Peptide compound and application thereof, and composition containing peptide compound |
Non-Patent Citations (4)
Title |
---|
DATABASE PUBCHEM SUBSTANCE 22 February 2011 (2011-02-22), ANONYMOUS : "AKOS000648614", XP055871764, retrieved from PUBCHEM Database accession no. AKOS000648614 * |
DATABASE PUBCHEM SUBSTANCE 31 March 2020 (2020-03-31), ANONYMOUS : "2-(2-(1,3-Dioxoisoindolin-2- yl)acetamido)acetyl chloride", XP055871765, retrieved from PUBCHEM Database accession no. 405014557 * |
DATABASE PUBCHEM SUBSTANCE 7 March 2011 (2011-03-07), ANONYMOUS : "AC1MBWCP", XP055871767, retrieved from PUBCHEM Database accession no. AC1MBWCP * |
PéREZ-PICASO LEMUEL; OLIVO HORACIO F.; ARGOTTE-RAMOS ROCíO; RODRíGUEZ-GUTIéRREZ MARíA; RIOS MAR: "Linear and cyclic dipeptides with antimalarial activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 22, no. 23, 1 January 1900 (1900-01-01), AMSTERDAM, NL , pages 7048 - 7051, XP028955898, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2012.09.094 * |
Also Published As
Publication number | Publication date |
---|---|
CN115515937A (en) | 2022-12-23 |
AU2021267384A1 (en) | 2023-01-05 |
US20230159450A1 (en) | 2023-05-25 |
EP4146629A1 (en) | 2023-03-15 |
CA3174239A1 (en) | 2021-11-11 |
IL297452A (en) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11787836B2 (en) | Method for synthesizing peptide containing N-substituted amino acid | |
US11414405B2 (en) | Compounds for use in synthesis of peptidomimetics | |
WO2000018790A1 (en) | Synthesis of cyclic peptides | |
CN111378028A (en) | Synthesis of acylated GLP-1 compounds and modified groups thereof | |
Ruczyński et al. | Problem of aspartimide formation in Fmoc‐based solid‐phase peptide synthesis using Dmab group to protect side chain of aspartic acid | |
WO2019101939A1 (en) | Method for preparing peptides | |
EP1037904A2 (en) | Branched building units for synthesizing cyclic peptides | |
AU2021267384A1 (en) | Dimers for use in synthesis of peptidomimetics | |
US20220306577A1 (en) | Thiosemicarbazates and uses thereof | |
US5942601A (en) | Peptide synthesis with sulfonyl protecting groups | |
RU2777327C1 (en) | Method for synthesising peptides | |
US20200354404A1 (en) | Peptidomimetic agents, synthesis and uses thereof | |
Wang | Amino Acids: Insights and Roles in Heterocyclic Chemistry: Volume 1: Protecting Groups | |
Hall | Poster presentation abstracts | |
Eritja Casadellà et al. | Solid-phase peptide synthesis using N-alpha-trityl-amino acids | |
EP0224088A2 (en) | Process for the solid-phase synthesis of retro-inverso peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21800750 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3174239 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021800750 Country of ref document: EP Effective date: 20221208 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021267384 Country of ref document: AU Date of ref document: 20210507 Kind code of ref document: A |